Chongqing iCELL Biotechnology

Chongqing iCELL Biotechnology is a clinical-stage biotechnology company focused on the development of innovative cell therapies, particularly those derived from induced pluripotent stem cells (iPSCs). The company operates a comprehensive platform for the generation of off-the-shelf CAR-T and CAR-NK cell products designed to treat various cancers and autoimmune diseases. By utilizing iPSC technology, iCELL aims to provide standardized, scalable, and cost-effective alternatives to traditional autologous cell therapies. Their pipeline includes both autologous CAR-T programs and next-generation universal cell products targeting hematological malignancies and solid tumors. The company maintains integrated R&D and GMP manufacturing facilities in Chongqing to support its clinical pipeline and commercialization goals.